Santhera shares plummet after negative CHMP opinion

ZURICH (Reuters) - Swiss drugmaker Santhera's shares plunged nearly 60 percent in early trading on Friday, after a European panel recommended against approving one of its drugs to be used in patients with Duchenne muscular dystrophy (DMD).